Diagnostic Center | December 17, 2024
Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Subscribe To Our Newsletter & Stay Updated
